How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal estrogen/progestin interventions trial

Archives of Internal Medicine

Volumn 160, Issue 20, 2000, Pages 3065-3071

  Greendale, Gail A ^a   Wells, Bradley ^b   Marcus, Robert ^c   Barrett Connor, Elizabeth ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ANALYTIC METHOD; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HIP RADIOGRAPHY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORBIDITY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; SPINE RADIOGRAPHY;

EID: 0034645459     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.20.3065     Document Type: Article

References (26)

1. Sources of variability in bone mineral density measurements: Implications for study design and analysis of bone loss
2. Rationale, design, and conduct of the PEPI Trial
3. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
4. Effects of hormone therapy on endometrial histology in postmenopausal women
5. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
6. Leisure, home, and occupational physical activity and cardiovascular risk factors in postmenopausal women: The Postmenopausal Estrogens/Progestins Intervention (PEPI) Study
7. Lifestyle factors and bone mineral density: The Postmenopausal Estrogen/Progestin Interventions study
8. A simple method for the assay of eight steroids in small volumes of plasma
9. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives
10. Correlates of bone mineral density in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
11. The pathophysiology and treatment of postmenopausal osteoporosis: An evidence-based approach to estrogen replacement therapy
12. Estrogen therapy arrests bone loss in elderly women
13. Site of osteodensitometry in perimenopausal women: Correlation and limits of agreement between anatomic regions
14. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
15. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
16. Pathophysiological mechanisms of estrogen effect on bone metabolism, dose-response relationships in early postmenopausal women
17. Effects of alendronate and estrogen, alone or in combination on bone mass and turnover in postmenopausal osteoporosis
18. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
19. Absorption and metabolic effects of different types of estrogens and progestins
20. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study
21. Hormonal predictors of bone loss in elderly women: A prospective study
22. Endogenous hormones and the risk of hip and vertebral fractures among older women
23. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
24. Longitudinal studies on the rate of decline in renal function with age